Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company.

It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).

[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.

[2][3][4] The drug is a peptide with amino acid sequence[5] where superscript numbers refer to unique chemical modifications: This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.